Eğitim ve Uzmanlık
1997-2003 İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi
2004-2010 İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi İç Hastalıkları ABD
2011-2014 Kartal Dr. Lütfi Kırdar Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Kliniği

Deneyim
2004-2010 İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi İç Hastalıkları İhtisası
2010-2011 Sinop Durağan Devlet Hastanesi  mecburi hizmet
2011-2014 Dr.Lütfi Kırdar Eğitim ve Araştırma Hastanesi Onkoloji kliniği Tıbbi Onkoloji İhtisası
2015-2016 Kocaeli Devlet Hastanesi  mecburi hizmet
2016-2020 Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesi Onkoloji BD Tıbbi Onkoloji uzmanı
2020-2024 Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesi Onkoloji BD Tıbbi Onkoloji Doç.Dr
2024-2025 Ataşehir Memorial Hastanesi
2024-2025 Üsküdar Üniversitesi İç hastalıkları ABD, Tıbbi Onkoloji BD öğretim üyesi
2025- Halen Göztepe Medical Park Hastanesi

Kurs ve Sertifikalar
Geleceğin Akademisyenleri Kursu
İleri Laparoskopik Cerrahi Kursu
Temel Robotik Cerrahi Kursu
Terapötik Aferez Sertifikalı Eğitim Program
İyi Klinik Uygulamalar Kursu

Mesleki Üyelikler
Türk Tabipler Birliği
Türk Tıbbi Onkoloji Derneği
ESMO Avrupa Onkoloji Derneği
MONDER Marmara Onkoloji Derneği
Kemoterapi derneği

SCI, SCI-Expanded, PubMed, Web of Science İndeksli Dergilerde Yayımlanan Makaleler:

1.Ercelep O, Alan O, Sahin D, Telli TA, Salva H, Tuylu TB, Babacan NA, Kaya S, Dane F, Ones T, Alkis H, Adli M, Yumuk F. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer. Clin Transl Oncol. 2019 Apr;21(4):499-504. doi: 10.1007/s12094-018-1949-6. Epub 2018 Sep 18. PMID: 30229391.

2.Ercelep O, Alan O, Telli TA, Tuylu TB, Arıkan R, Demircan NC, Simsek ET, Babacan NA, Kaya S, Dane F, Bozkurtlar E, Ones T, Lacin T, Yumuk PF. Differences in PET/CT standardized uptake values involvement and survival compared to histologic subtypes of lung adenocarcinoma. Tumori. 2021 Jun;107(3):231-237. doi: 10.1177/0300891620950475. Epub 2020 Sep 2. PMID: 32878562.

3.Ercelep O, Gumus M. Comparison of clinicopathologic and survival characteristics of high grade endometrial cancers; single center experience. Curr Probl Cancer. 2019 Apr;43(2):160-166. doi: 10.1016/j.currproblcancer.2018.07.004. Epub 2018 Jul 21. PMID: 30122267.

4. Ercelep O, KESER S ,Ozcelik M, Basar M. ACK1/TNK2 Tyrosine Kinase Overexpression Role in Gastric Cancer ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI ARTICLE International Journal of Hematology and Oncology UHOD Number: 2 Volume: 29 Year: 2019  doi: 10.4999/uhod.192412

5.Ercelep O, Ozcelik M, Gumus M. Association of lymphadenectomy and survival in epithelial ovarian cancer. Curr Probl Cancer. 2019 Apr;43(2):151-159. doi: 10.1016/j.currproblcancer.2018.08.002. Epub 2018 Aug 17. PMID: 30149960.

6.Ercelep O, Ozdemir N, Turan N, Topcu TO, Uysal M, Tanriverdi O, Demirci U, Taskoylu BY, Urakcı Z, Duran AO, Aksoy A, Menekse S, Ozcelik M, Gumus M. Retrospective evaluation of patients diagnosed solid pseudopapillary neoplasms of the pancreas. Curr Probl Cancer. 2019 Feb;43(1):27-32. doi: 10.1016/j.currproblcancer.2018.06.014. Epub 2018 Jul 19. PMID: 30104029.

7.Ercelep O, Topcu TO, Bayoglu IV, Ekinci AS, Koca S, Kavgaci H, Ozcelik M, Alacacioglu A, Uzunoglu S, Bozkurt O, Ulas A, Aksoy A, Taskoylu BY, Gumussay O, Yaman S, Uysal M, Aydin D, Gumus M. Retrospective multicenter evaluation of patients diagnosed with mucosal melanoma: a study of Anatolian Society of Medical Oncology. Tumour Biol. 2016 Sep;37(9):12033-12038. doi: 10.1007/s13277-016-5076-0. Epub 2016 May 12. PMID: 27173124.

8.Ercelep OB, Caglar E, Dobrucali A. The prevalence of gastroesophageal reflux disease among hospital employees. Dis Esophagus. 2014 Jul;27(5):403-8. doi: 10.1111/j.1442-2050.2012.01402.x. Epub 2012 Sep 28. PMID: 23020266.

9.Ercelep Ö,1 Telli TA,  Alan Ö,  Hasanov R, Şimşek ET, Babacan NA, Kaya S, Kaya H, Dane F, Yumuk F Smokers having Activating EGFR Mutant Non-Small Cell Lung Cancer Might Benefit from EGFR-TKI Treatment –Single-Center Experience Turk J Oncol 2020;35(3):334–9 doi: 10.5505/tjo.2020.2207

10.Akdeniz N, Küçüköner M, Kaplan MA, Urakçı Z, Karhan O, Sezgin Y, Bilen E, Ebinç S, Teke F, Laçin Ş, Alan Ö, Ercelep Ö, Işıkdoğan A, Yumuk PF. Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer. Int J Clin Oncol. 2020 Dec;25(12):2015-2024. doi: 10.1007/s10147-020-01767-x. Epub 2020 Aug 14. PMID: 32797321.

11.Alan O, Akin Telli T, Aktas B, Koca S, Ökten IN, Hasanov R, Basoglu T, Arikan R, Demircan NC, Ercelep O, Kaya S, Ugurlu MU, Kaya H, Akgul Babacan N, Dane F, Yumuk PF. Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment? World J Surg Oncol. 2020 Sep 9;18(1):242. doi: 10.1186/s12957-020-02019-y. PMID: 32907593; PMCID: PMC7488234.

12.Alan O, Akin Telli T, Ercelep O, Tanrikulu Simsek E, Basoglu Tuylu T, Mutis A, Hasanov R, Kaya S, Akgül Babacan N, Dane F, Yumuk PF. Chordoma: a case series and review of the literature. J Med Case Rep. 2018 Aug 27;12(1):239. doi: 10.1186/s13256-018-1784-y. PMID: 30145982; PMCID: PMC6109974.

13.Alan O, Telli TA, Basoğlu T, Arikan R, Demircan NC, Ercelep O, Bozkurt S, Atasoy BM, Dane F, Yumuk PF. Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment. Clin Neurol Neurosurg. 2020 Sep;196:105976. doi: 10.1016/j.clineuro.2020.105976. Epub 2020 May 30. PMID: 32531614.

14.Alan O, Telli TA, Basoğlu T, Arikan R, Demircan NC, Ercelep O, Sakar M, Bozkurt S, Atasoy BM, Dane F, Ziyal Mİ, Yumuk PF. Impact of prognostic nutritional index on survival in recurrent glioblastoma. Neurocirugia (Astur : Engl Ed). 2021 Jan 13:S1130-1473(20)30136-6. English, Spanish. doi: 10.1016/j.neucir.2020.11.005. Epub ahead of print. PMID: 33454185.

15.Alan O, Telli TA, Ercelep O, Hasanov R, Simsek ET, Mutis A, Ones T, Kaya H, Yumuk PF. A case of primary squamous cell carcinoma of the breast with pathologic complete response after neoadjuvant chemotherapy. Curr Probl Cancer. 2019 Aug;43(4):308-311. doi: 10.1016/j.currproblcancer.2018.04.003. Epub 2018 May 9. PMID: 29880396.

16.Arıkan R, Telli TA, Demircan NC, Başoğlu T, Ercelep Ö, Atasoy BM, Özgüven S, Dane F, Yumuk PF. Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature. Curr Probl Cancer. 2021 Apr;45(2):100668. doi: 10.1016/j.currproblcancer.2020.100668. Epub 2020 Oct 22. PMID: 33127167.

17.Aydin D, Bilici A, Yavuzer D, Kefeli U, Tan A, Ercelep O, Mert A, Yuksel S, Ozcelik M, Isik D, Surmeli H, Odabasi H, Aliustaoglu M. Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy. Clin Transl Oncol. 2015 Aug;17(8):604-11. doi: 10.1007/s12094-015-1283-1. Epub 2015 Mar 19. PMID: 25786367.

18.Aydin D, Sendur MA, Kefeli U, Ustaalioglu BB, Aydin  O, Yildirim E, Işık D, Ozcelik M, Surmeli H, Oyman A, Işık S, Sener N, Ercelep Ö, Odabas H, Aliustaoglu M, Gumus M (2017). Evaluation Of Bevacizumab in Advanced Small Bowel Adenocarcinoma. Clin Colorectal Cancer, Doi: 10.1016/J.Clcc.2016.04.013.

19.Basoglu T, Telli TA, Demircan NC, Arikan R, Ercelep O, Ozguven S, Soysal S, Memisoglu A, Dane F, Yumuk PF. A rare case of gastric cancer with bilateral breast metastasis during pregnancy. J Oncol Pharm Pract. 2021 Jan;27(1):220-226. doi: 10.1177/1078155220925156. Epub 2020 May 23. PMID: 32448025.

20.Başoğlu T, Akar KE, Bağcı P, Akgül Babacan N, Öztürk MA, Öztürk FE, Demircan NC, Arikan R, Akın Telli T, Ercelep Ö, Dane F, Yumuk PF. Prognostic Value of Tissue-Resident Memory T Cells and Tumor Microenvironmental Features in Resected Pancreatic Adenocarcinoma. Balkan Med J. 2021 Dec 20. doi: 10.5152/balkanmedj.2021.21122. Epub ahead of print. PMID: 34928235.

21.Cicin İ, Özatlı T, Türkmen E, Özturk T, Özçelik M, Çabuk D, Gökdurnalı A, Balvan Ö, Yıldız Y, Şeker M, Özdemir N, Yapar B, Tanrıverdi Ö, Günaydin Y, Menekşe S, Öksüzoğlu B, Aksoy A, Erdogan B, Bekir Hacıoglu M, Arpaci E, Sevinç A. Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas. Balkan Med J. 2016 Sep;33(5):517-524. doi: 10.5152/balkanmedj.2016.151268. Epub 2016 Sep 1. PMID: 27761279; PMCID: PMC5056654.

22.Demircan NC, Akın Telli T, Başoğlu Tüylü T, Arıkan R, Kocakaya D, Şahin AA, Ercelep Ö, Dane F, Yumuk PF. QT interval prolongation related to afatinib treatment in a patient with metastatic non-small-cell lung cancer. Curr Probl Cancer. 2020 Dec;44(6):100594. doi: 10.1016/j.currproblcancer.2020.100594. Epub 2020 May 27. PMID: 32505368.

23.Demircan NC, Alan Ö, Başoğlu Tüylü T, Akın Telli T, Arıkan R, Çiçek FC, Ercelep Ö, Öztürk MA, Alsan Çetin İ, Ergelen R, Tinay İ, Akgül Babacan N, Kaya S, Dane F, Yumuk PF. Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib. J Oncol Pharm Pract. 2020 Jul;26(5):1147-1155. doi: 10.1177/1078155219890032. Epub 2019 Dec 2. PMID: 31793376.

24.Demircan NC, Dane F, Ozturk MA, Babacan NA, Besiroglu M, Kaya S, Ercelep O, Tanrikulu E, Halil S, Koca S, Alan O, Hasanov R, Yumuk PF. Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy. J BUON. 2019 Jul-Aug;24(4):1494-1500. PMID: 31646797.

25.Demirelli B, Babacan NA, Ercelep Ö, Öztürk MA, Kaya S, Tanrıkulu E, Khalil S, Hasanov R, Alan Ö, Telli TA, Koca S, Arıbal ME, Kuzan B, Dane F, Yumuk PF. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer. Nutr Cancer. 2021;73(2):230-238. doi: 10.1080/01635581.2020.1749290. Epub 2020 Apr 9. PMID: 32270713.

26.Dinc NS, Aydın K, Odabas H, Ercelep O, Tufan G, Seker M, Yasar N, Aydin D, Yuksel S, Mert A, Ozcelik M, Korkmaz T, Yildiz R, Aliustaoglu M, Mayadagli A, Dane F, Gumus M. Pretreatment PET/CT Standardized Uptake Values Play a Role in Predicting Response to Treatment and Survival in Patients with Small Cell Lung Cancer. Oncol Res Treat. 2016;39(3):130-4. doi: 10.1159/000444272. Epub 2016 Feb 23. PMID: 27030981.

27.Gumusay O, Coskun U, Akman T, Ekinci AS, Kocar M, Erceleb OB, Yazıcı O, Kaplan MA, Berk V, Cetin B, Taskoylu BY, Yildiz A, Goksel G, Alacacioglu A, Demirci U, Algin E, Uysal M, Oztop I, Oksuzoglu B, Dane F, Gumus M, Buyukberber S. Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology. J Cancer Res Clin Oncol. 2014 Jan;140(1):151-7. doi: 10.1007/s00432-013-1553-7. Epub 2013 Nov 29. PMID: 24292400.

28.Kaya S, Aktas B, Tanrikulu Sismek E, Akif Ozturk M, Dede F, Kaya H, Ugurlu U, Ozgen Z, Koca S, Halil S, Hasanov R, Alan O, Akgul Babacan N, Ercelep O, Dane F, Gumus M, Yumuk F. Changes in 18F-FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone-positive breast cancer. J BUON. 2017 Sep-Oct;22(5):1191-1198. PMID: 29135102.

29.Kefeli U, Yildirim ME, Aydin D, Madenci OC, Yasar N, Sener N, Mert AG, Yuksel S, Ercelep OB, Korkmaz T, Yildiz R, Gumus M. Netrin-1 concentrations in patients with advanced gastric cancer and its relation with treatment. Biomarkers. 2012 Nov;17(7):663-7. doi: 10.3109/1354750X.2012.709882. Epub 2012 Aug 13. PMID: 22889408.

30.Korkmaz T, Seber S, Kefeli U, Sari E, Canhoroz M, Oven B, Yildirim E, Yasar N, Aydin D, Balvan O, Sener N, Yuksel S, Mert A, Polat O, Yumuk F, Kanat O, Gumus M, Turhal NS. Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis. Clin Transl Oncol. 2013 Jul;15(7):535-40. doi: 10.1007/s12094-012-0960-6. Epub 2012 Nov 10. PMID: 23143955.

31.Oruc Z, Kaplan MA, Geredeli C, Yildirim Sari N, Ozaslan E, Aytekin A, Tamer Elkiran E, Koca S, Dogan M, Turan N, Yuce O, Sevinc A, Ercelep O, Isikdogan A. Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study. J BUON. 2020 Mar-Apr;25(2):641-647. PMID: 32521847.

32.Oven Ustaalioglu BB, Balvan O, Bilici A, Develi A, Aliustaoglu M, Vardar FA, Erkol B. The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival. Clin Transl Oncol. 2015 Nov;17(11):895-902. doi: 10.1007/s12094-015-1323-x. Epub 2015 Jun 17. PMID: 26081286.

33.Ozcelik M, Korkmaz T, Odabas H, Gemici C, Ercelep O, Yuksel S, Mert AG, Surmeli H, Isik D, Aydin D, Seker M, Mayadagli A, Ozdemir P, Aliustaoglu M, Gumus M. Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients. Tumour Biol. 2016 Jul;37(7):8901-7. doi: 10.1007/s13277-015-4776-1. Epub 2016 Jan 11. PMID: 26753955.

34.Ozcelik M, Odabas H, Ercelep O, Yuksel S, Mert AG, Aydin D, Surmeli H, Isik D, Isik S, Oyman A, Oven Ustaalioglu BB, Aliustaoglu M, Gumus M. The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients. Clin Transl Oncol. 2016 Jun;18(6):617-24. doi: 10.1007/s12094-015-1408-6. Epub 2015 Oct 12. PMID: 26459249.

35.Ozcelik M, Seker M, Eraslan E, Koca S, Yazilitas D, Ercelep O, Ozaslan E, Kaya S, Hacibekiroglu I, Menekse S, Aksoy A, Taskoylu BY, Varol U, Arpaci E, Ciltas A, Oksuzoglu B, Zengin N, Gumus M, Aliustaoglu M. Evaluation of prognostic factors in localized high-grade undifferentiated pleomorphic sarcoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology. Tumour Biol. 2016 Apr;37(4):5231-7. doi: 10.1007/s13277-015-4359-1. Epub 2015 Nov 10. PMID: 26553363.

36.Özçelik M, Ercelep Ö, Keser S, Özdemir NB, Başar M, Odabaş H, Oyman A, Işık S, Özçelik S, Aliustaoğlu M (2020). PTK-7 Expression in Gastric Cancer: A Prognostic Determinant. Balkan Med J, Doi:10.4274/Balkanmedj.Galenos.2019.2019.8.12. Epub 2019 Dec 10.

37.Özçelik M, Odabaş H, Ercelep Ö, Yüksel S, Mert AG, Aydın D, Sürmeli H, Işık D, Işık S, Oyman A, Ustaalioğlu BBÖ, Aliustaoğlu M, Gümüş Mahmut (2015). The Efficacy and Safety of Capecitabine plus Bevacizumab Combination As First-Line Treatment In Elderly Metastatic Colorectal Cancer Patients. Clinical And Translational Oncology, Doi: 10.1007 /S12094-015-1408-6.

38.Telli TA, Demircan NC, Alan O, Tuylu TB, Arikan R, Ercelep O, Atıcı AE, Ergelen R, Seven IE, Babacan NA, Kaya S, Dane F, Fulden Yumuk P. A rare case of primary rectal choriocarcinoma and review of the literature. J Oncol Pharm Pract. 2020 Jun;26(4):989-994. doi: 10.1177/1078155219875510. Epub 2019 Sep 23. PMID: 31547751.

39.Turan N, Benekli M, Dane F, Unal OU, Kara HV, Koca D, Balvan O, Eren T, Tastekin D, Helvaci K, Berk V, Demirci U, Ozturk SC, Dogan E, Cetin B, Kucukoner M, Tonyali O, Tufan G, Oztop I, Gumus M, Coskun U, Uner A, Ozet A, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer. Thorac Cancer. 2014 Sep;5(5):398-404. doi: 10.1111/1759-7714.12107. Epub 2014 Aug 25. PMID: 26763794; PMCID: PMC4704370.

40.Turan N, Benekli M, Unal OU, Unek İT, Tastekin D, Dane F, Algın E, Ulger S, Eren T, Topcu TO, Turkmen E, Babacan NA, Tufan G, Urakci Z, Ustaalioglu BO, Uysal OS, Ercelep OB, Taskoylu BY, Aksoy A, Canhoroz M, Demirci U, Dogan E, Berk V, Balakan O, Ekinci AŞ, Uysal M, Petekkaya İ, Ozturk SC, Tonyalı Ö, Çetin B, Aldemir MN, Helvacı K, Ozdemir N, Oztop İ, Coskun U, Uner A, Ozet A, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma. Chin J Cancer Res. 2015 Aug;27(4):408-16. doi: 10.3978/j.issn.1000-9604.2015.08.03. PMID: 26361410; PMCID: PMC4560744.

41.Dogan, I.; Aksoy, S.; Cakar, B.; Basaran, G.; Ercelep, O.; Molinas Mandel, N.; Korkmaz, T.; Gokmen, E.; Sener, C.; Aydiner, A.; et al. Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group. Cancers 2023, 15, 1667. https://doi.org/10.3390/cancers15061667 

42.Çağlar Ünal, Abdulmunir Azizy, Senem Karabulut, Didem Taştekin, Arif Akyıldız, Serkan Yaşar, Şuayib Yalçın, Eyüp Çoban, Türkkan Evrensel, Ziya Kalkan, Zeynep Oruç, Sümeyra Derin, Zeynep Hande Turna, Doğan Bayram, Fahriye Tuğba Köş, Mehmet Ali Nihat Şendur, Nadiye Sever, Özlem Ercelep, Mustafa Seyyar, Umut Kefeli, Kazım Uygun, Melike Özçelik, Sercan Ön, Ulus Ali Şanlı, Kübra Canaslan, İlkay Tuba Ünek, Kadriye Bir Yücel, Nuriye Özdemir, Ozan Yazıcı, Halil Göksel Güzel, Derya Kıvrak Salim, Sema Sezgin Göksu, Ali Murat Tatlı, Çetin Ordu, Oğuzhan Selvi, Abdullah Sakin, Mehmet Emin Büyükbayram, Bengü Dursun, Yüksel Ürün, Hacı Arak, Gözde Ağdaş, Muzaffer Uğraklı, Engin Hendem, Melek Karakurt Eryılmaz, Burak Bilgin, Atakan Topçu, Melih Şimşek, Mahmut Büyükşimşek, Büşra Akay, Gülçin Şahingöz Erdal, Fatih Karataş, Özkan Alan, Melek Çağlayan, Fatma Akdağ Kahvecioğlu, Ayşe Demirci, Nail Paksoy, Bülent Çetin, Mahmut Gümüş, Naziye Ak, Yasemin Aydınalp, Semra Paydaş, Deniz Can Güven, Saadettin Kılıçkap, Sezer Sağlam, Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group, The Oncologist, Volume 28, Issue 10, October 2023, Pages 875–884, https://doi.org/10.1093/oncolo/oyad257

43.Osman Köstek, Ahmet Demirel, Muhammet Bekir Hacıoğlu, Didem Tastekin, Senem Karabulut, Abidin Gündogdu, Nadiye Sever, Murat Ayhan, Abdussamed Çelebi, Nargiz Majidova, Alper Yaşar, Yeşim Ağyol, Pınar Erel, Erkam Kocaaslan, Ali Kaan Güren, Rukiye Arıkan, Selver Isık, Ozlem Ercelep, Sema Sezgin Goksu, Celal Alandag, İrem Bilgetekin, Burcu Caner, Ahmet Bilge Sahin, Ahmet Gulmez, Baran Akagunduz, Fatih Kose, Muhammet Ali Kaplan, Ender Dogan, Teoman Sakalar, Deniz Can Guven, Mustafa Gurbuz, Yakup Ergun, Mustafa Karaagac, Sema Turker, Ozlem Ozkul, Birol Yıldız, Süleyman Sahin, Atike Gokcen Demiray, Murat Sari, Bülent Erdogan, İlhan Hacıbekiroglu, Ömür Berna Çakmak Öksüzoğlu, Saadettin Kilickap, Ahmet Bilici, İbrahim Vedat Bayoglu, Sernaz Topaloglu & İrfan Cicin (2024) The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing, Journal of Chemotherapy, DOI: 10.1080/1120009X.2024.2305066

44.Arikan R, Ozguven S, Telli TA, et al. Prognostic significance of 18F-FDG PET/CT indices in metastatic renal cell cancer and evaluation of revised IMDC risk model by including 18F-FDG PET-CT parameters. Acta Radiologica. 2023;64(5):2040-2049. doi:10.1177/02841851221140504

45.Ahmet Ozveren, Derya Hopanci Bicakli, Gamze Gultekin, Timucin Cil, Dilek Dogan, Canan Zengin, Ahmet Bilici, Songül Sabir, Ozlem Ercelep, Feyzanur Eksi, Fatih Selcukbiricik, Meltem Yilmaz, Gozde Ergene, Ali Murat Tatli, Feray Karsli Aksoy, Omer Dizdar, Hasan Çağrı Yıldırım, Nesrin Ozmen, Ulus Ali Sanli, and Bulent Karabulut Alterations in muscle strength among patients with GI cancers receiving oral nutritional support as soon as malnutrition was detected: ONMUS study.. JCO 42, 741-741(2024).DOI:10.1200/JCO.2024.42.3_suppl.741

46.Bayoğlu, İbrahim Vedat, Javid Hüseynov, Alper Topal, Nadiye Sever, Nargiz Majidova, Abdussamet Çelebi, Alper Yaşar, Rukiye Arıkan, Selver Işık, Muhammet Bekir Hacıoğlu, ,Özlem Ercelep et al. 2023. "PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score" Journal of Clinical Medicine 12, no. 19: 6420. doi.org/10.3390/jcm12196420

47.Rukiye Arikan,1 Tugba Akin Telli,2 Selver Isik,1 Murat Sari,1 Osman Kostek,1 Ozlem Ercelep,1 Ibrahim Vedat Bayoglu Evaluation of Clinicopathological Characteristics and Survival Outcomes of Young Gastric Cancer Patients, Single Center Experience DOI: 10.14744/ejmi.2023.43719EJMI 2023;7(3):296–302

48.R.  ARIKAN, Üstün H. S., Demircan N. C., Işik S., Telli T. A., Yaşar A., Çelebi A., Majidova N., Sever N., ÇELİKEL Ç., Sari M., Ercelep Ö., Köstek O., Bayoğlu I. V. Et Al. , "Prognostic Significance of Mucinous Histology in Metastatic Colorectal Cancer Patients Treated with Regorafenib,"  Journal of Oncological Science , vol.9, no.2, pp.53-61, 2023    

49.  Tugba Akin Telli a, Ozkan Alan a f, Nazim Can Demircan a, Nisanur Sariyar b, Rukiye Arikan a, Tugba Basoglu a, Alper Yasar a, Abdussamet Celebi a, Selver Isik a, Omer Sofulu c, Bulent Erol c, Huseyin Kemal Turkoz d, Zerrin Ozgen e, Ozlem Ercelep a, Faysal Dane a, Perran Fulden Yumuk a f Age-adjusted Charlson Comorbidity Index is a valuable prognostic tool in operable soft tissue sarcoma of trunk and extremities   Orthopaedics & Traumatology: Surgery & ResearchVolume 109, Issue 3, May 2023, 103491

50.Basoglu, Tugba; Babacan, Nalan A.1; Ozturk, Fatih E.2; Arikan, Rukiye; Demircan, Nazim C.; Telli, Tugba Akin; Ercelep, Ozlem; Dane, Faysal; Yumuk, Perran F.. Prognostic value of Gustave Roussy immune score in operable pancreatic adenocarcinoma. Indian Journal of Cancer 60(2):p 179-184, Apr–Jun 2023. | DOI: 10.4103/ijc.IJC_1049_20

51.Arikan, R., Atci, M. M., Ay, S., Ayhan, M., Demircan, N. C., Telli, T. A., Çelebi, A., Yaşar, A., Işik, S., Celikel, C., Balvan, O., Bayoglu, I. V., Kostek, O., Dane, F., Yumuk, P. F."Prognostic significance of mucinous histology in left‑sided metastatic colorectal cancers with wild‑type RAS and evaluation of backbone chemotherapy regimens". Oncology Letters 25.5 (2023): 208.

52.Cihan Erol ; Emre Yekedüz; Deniz Tural; Serdar Karakaya; Nihan Şentürk Öztaş; Gökhan Uçar  Saadettin Kılıçkap; İsmail Ertürk; Özlem Nuray Sever; Çağatay Arslan; Ahmet Küçükarda; Orçun Can; Özlem Balvan; Satı Coşkun Yazgan ; Mustafa Özgüroğlu  ; Berna Öksüzoğlu; Mehmet Ali Nahit Şendur; Yüksel Ürün Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium Urol Int (2023) 107 (6): 595–601.https://doi.org/10.1159/000528994

53.Kadriye Bir Yücel, Emre Yekedüz, Serdar Karakaya, Deniz Tural, İsmail Ertürk, Cihan Erol, Özlem Ercelep, Nihan Şentürk Öztaş, Çağatay Arslan, Gökhan Uçar, Ahmet Küçükarda, Özlem Nuray Sever, Saadettin Kılıçkap, Orçun Can, Satı Coşkun Yazgan, Berna Öksüzoğlu, Nuri Karadurmuş, Mehmet Ali Şendur & Yüksel Ürün The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors Nature 2045-2322 /doi.org/10.1038/s41598-022-20056-3

54.Emre Yekedüz, Deniz Tural, İsmail Ertürk, Serdar Karakaya, Cihan Erol, Özlem Ercelep, Çağatay Arslan, Özlem Nuray Sever, Saadettin Kılıçkap, Nihan Şentürk Öztaş, Ahmet Küçükarda, Orçun Can, Berna Öksüzoğlu, Mehmet Ali Şendur, Nuri Karadurmuş & Yüksel Ürün The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study Journal of Cancer Research and Clinical Oncology Volume 148, pages 3537–3546, (2022)

55.Tugba Akin Telli Onur Bugdayci, Ozkan Alan ,Nisanur Sariyar,Selver Isik,Rukiye Arikan Icon,Alper Yasar,Nargiz Majidova,Abdussamet Celebi,Bulent Erol ,Zerrin Ozgen,Osman Kostek ,Ibrahim Vedat Bayoglu ,Ozlem Ercelep, Faysal Dane &Perran Fulden Yumuk Impact of Skeletal Muscle Measurements by Chest Computed Tomography on Survival and Postoperative Complications in Patients with Soft Tissue Sarcoma Nutrition and Cancer Volume 74, 2022 - Issue 7 https://doi.org/10.1080/01635581.2022.2063349

56.Nargiz MAJIDOVA1 , Fatih SIMSEK2 , Sedat BITER3 , Sendag YASLIKAYA3 , Mustafa SEYYAR4 , Mustafa Emre DUYGULU5 , Murat ARCAGOK6 , Muhammed Fatih KIRCALI2 ,Nadiye SEVER1 , Erkam KOCAASLAN1 , Pinar EREL1 , Yesim AGYOL1 , Ali Kaan GUREN1 , Abdussamet CELEBI1 , Rukiye ARIKAN1 , Selver ISIK1 , Ozlem ERCELEP1 , Murat SARI1 , Ibrahim Vedat BAYOGLU1 , Osman KOSTEK1Prognostic Factors Associated with Resected Osteosarcoma: Efficacy of Adjuvant Setting, Real-World ExperienceNumber: 1 Volume: 34 Year: 2024 1 ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI ARTICLE International Journal of Hematology and Oncology doi: 10.4999/uhod.

57.Nargiz Majidova; Murat Sari; Fatma Akdag Kahvecıglu; Erkan Ozcan; Mutıanur Ozkorkmaz Akdag; Akıf Dogan; Sedat Yıldırım; Sermın Dınc Sonusen; Emıl Yunusov; Alper Yasar; Abdussamet Celebi; Nadıye Sever; Erkam Kocaaslan; Pınar Erel; Yesım Agyol; Ali Kaan Guren; Rukiye Arikan; Selver Işık; Ozlem Balvan; Caglayan Geredeli; Kazım Uygun; Ilhan Hacıbekiroğlu; Osman Kostek; İbrahim Vedat Bayoğlu Clinicopathologic Features And Efficacy Of Induction Chemotherapy In Nasopharyngeal Carcinoma: Real-World Experience Oncol Res Treat 1.https://doi.org/10.1159/000537988

58.RUKIYE ARIKAN , MUHAMMED MUSTAFA ATCI , SEVAL AY , MURAT AYHAN , NAZIM CAN DEMIRCAN , TUĞBA AKIN TELLI , ABDUSSAMET ÇELEBI , ALPER YAŞAR , SELVER IŞIK , CIGDEM CELIKEL , OZLEM BALVAN , IBRAHIM VEDAT BAYOGLU , OSMAN KOSTEK , FAYSAL DANE and PERRAN FULDEN YUMUK Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens ONCOLOGY LETTERS 25: 208, 2023 DOI: 10.3892/ol.2023.13795

59. Ercelep Ö, Tataroğlu D, Özçelik M, Sürmeli H, Değirmenci M, İnanç M, Aliustaoğlu M, Gümüş M. Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer. Turk J Obstet Gynecol. 2020 Jun;17(2):123-127. doi: 10.4274/tjod.galenos.2020.90699. Epub 2020 Jul 29. PMID: 32850187; PMCID: PMC7406906.

 60.Ercelep O, Alan O, Telli TA,. Tuylu T, Arikan R, Demircan N,  Kocakaya D, Dane F,   Lacin T,  Bozkurtlar E, Yumuk PF Comparison of Seventh and Eighth Editions of TNM Staging Classification and Evaluation of Survivals in Operated Non-Small Cell Lung Carcinomas: Single Center Experience EJMI 2020;4(2):243–246 DOI: 10.14744/ejmi.2020.81008 EJMI 2020;4(2):243–246

61.Ercelep Ö,1 Telli TA,  Alan Ö,  Hasanov R, Şimşek ET, Babacan NA, Kaya S, Kaya H, Dane   F, Yumuk F Smokers having Activating EGFR Mutant Non-Small Cell Lung Cancer Might Benefit  from EGFR-TKI Treatment –Single-Center Experience Turk J Oncol 2020;35(3):334–9 doi: 10.5505/tjo.2020.2207

62. Veysel Başar,1 N. Onur Ermerak,2 Şehnaz Olgun Yıldızeli,3 Emine Bozkurtlar,4 Özlem Ercelep,5 Bülent Mutlu,6 Derya Kocakaya,3 G. Nural Bekiroğlu,7 Serpil Taş,1 Mehmed Yanartaş,1 Hasan Sunar,1 Koray Ak,8 Serdar Küçükoğlu,9 and Bedrettin Yıldızeli Results of surgical treatment of pulmonary artery sarcomas: Does histology affect survival? Turk Gogus Kalp Damar Cerrahisi Derg. 2023 Jul; 31(3): 388–397. Published online 2023 Jul 27. doi: 10.5606/tgkdc.dergisi.2023.23906

63. Ustaalioğlu BBÖ, Tilki M, Sürmelioğlu A, Bilici A, Gönen C, Ustaalioğlu R, Balvan Ö, Aliustaoğlu M. The clinicopathologic characteristics and prognostic factors of gastroesophageal junction tumors according to Siewert classification. Turk J Surg. 2017 Mar 1;33(1):18-24. doi: 10.5152/UCD.2017.3379. PMID: 28589183; PMCID: PMC5448566.

64. Tugba Basoglu,1 Salih Ozguven,2 Ceren Ozge Engur,2 Firat Akagunduz,3 Nazim Can Demircan,1 Rukiye Arikan,1 Fatma Temiz,3 Selma Sengun,3 Selver Isik,1 Tugba Akin Telli,1 Abdussamed Celebi, Alper Yasar, Ozlem Ercelep, Faysal Dane, Perran Fulden Yumuk, Prognostic Value Of PET/CT Determined Sarcopenia inPatients with Resected Ampullary Carcinoma DOI: 10.14744/ejmi.2023.28845 EJMI 2023;7(1):32–41

65. Tugba Akin Telli,1 Nisanur Sariyar,2 Ozkan Alan,1 Nazim Can Demircan,1 Selver Isik,1 Rukiye Arikan,1 Tugba Basoglu,1 Alper Yasar,1 Abdussamet Celebi,1 Omer Sofulu,3 Bulent Erol,3 Huseyin Kemal Turkoz,4 Zerrin Ozgen,5 Ozlem Ercelep,1 Faysal Dane,1 Perran Fulden Yumuk1 Preoperative Prognostic Nutritional Index is a Strong Predictor of Survival in Patients with Localized Soft Tissue Sarcoma DOI: 10.14744/ejmo.2021.74738 EJMI 2021;5(2):256–262

66. Tugba Basoglu,1 Nazim Can Demircan,1 Tugce Kubra Gunes,2 Mehmet Umut Capar,2 Merve Cinar,2 Rukiye Arikan,1 Tugba Akin Telli,1 Ozlem Ercelep,1 Faysal Dane,1 Perran Fulden Yumuk1 A Laboratory Prognostic Index Model for Predicting Survival in Patients with Malignant Pleural Mesothelioma DOI: 10.14744/ejmi.2022.38653 EJMI 2022;6(3):352–358

67. Tuğba Başoğlu, Nazım Can Demircan, Rukiye Arıkan, Tugba Akın Telli, Selver Işık, Alper Yasar, Abdussamet Çelebi, Özlem Ercelep, Faysal Dane, Perran Fulden YumukComparison of Resected Ampullary and Pancreatic Head Carcinomas: A Single-Center Experience DOI: 10.14744/scie.2022.95815 South. Clin. Ist. Euras. 2022;33(3):326-330

68. Rukiye Arikan,1 Tugba Akin Telli,1 Ozkan Alan,1 Nazim Can Demircan,1 Tugba Basoglu,1 Ozlem Ercelep,1 Handan Kaya,2 Onur Bugdayci,3 Umit Ugurlu,4 Zerrin Ozgen,5 Faysal Dane,1 Perran Fulden Yumuk1 1 Department of Internal Medicine, Division of MediClinicopathologic and Radiologic Characteristics of Pleomorphic Lobular Breast Cancer DOI: 10.14744/ejmi.2021.76855 EJMI 2021;5(1):148–152

69. Rukiye Arikan, Tugba Akin Telli, Selver Isik, Murat Sari, Osman Kostek, Ozlem Ercelep,1 Ibrahim Vedat Bayoglu1 Evaluation of Clinicopathological Characteristics and Survival Outcomes of Young Gastric Cancer Patients, Single Center Experience DOI: 10.14744/ejmi.2023.43719 EJMI 2023;7(3):296–302

70. Deliktaş Onur İ, Başoğlu T, Demircan NC, Akin Telli T, Arikan R, Ercelep Ö, Turhal NS, Öztürk MA, Yumuk PF, Dane F. Evaluating the performance of the MSKCC gastric cancer survival calculator in the Turkish population. Turk J Med Sci. 2024 Jul 4;54(6):1205-1214. doi: 10.55730/1300-0144.5901. eCollection 2024.PMID: 39734332 

71. Majidova N, Seyyar M, Bayraktar DI, Dinç G, İsgandarov E, Huseynov J, Yaşar A, Çelebi A, Sever N, Kocaaslan E, Erel P, Ağyol Y, Güren AK, Arıkan R, Işık S, Ercelep Ö, Demirağ G, Kefeli U, Köstek O, Bayoğlu İV, Sarı Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multi-centre study.M.Biomol Biomed. 2024 Oct 17;24(6):1776-1784. doi: 10.17305/bb.2024.10512.

 

72. Sever N, Yunusov E, Çelebi A, Yaşar A, Majidova N, Kocaaslan E, Erel P, Ağyol Y, Güren AK, Işık S, Arıkan R, Ercelep Ö, Köstek O, Bayoğlu İV, Sarıc M. Impact of renin angiotensin system inhibitors on survival of patients with metastatic non-small cell lung cancer.Ann Saudi Med. 2025 Jan-Feb;45(1):18-24. doi: 10.5144/0256-4947.2025.18. Epub 2025 Feb 6.PMID: 39929787 

 

73. Nadiye SEVER, Sedat YILDIRIM, Hacer Sahika YILDIZ, Sermin DINC SONUSEN, Abdussamet CELEBI, Nargiz MAJIDOVA, Alper YASAR, Erkam KOCAASLAN, Pinar EREL, Yesim AGYOL, Ali Kaan GUREN, Selver ISIK, Ozlem ERCELEP, Rukiye ARIKAN, Ibrahim Vedat BAYOGLU, Murat SARI, Osman KOSTEK Long-Term Survival and Disease-Free Rates in Locoregional Anal Squamous Cell Carcinoma: An Institutional Experience. UHOD , 2024 , 34 , 213-219

 

74. Nargiz MAJIDOVA, Fatih SIMSEK, Sedat BITER, Sendag YASLIKAYA, Mustafa SEYYAR, Mustafa Emre DUYGULU, Murat ARCAGOK, Muhammed Fatih KIRCALI, Nadiye SEVER, Erkam KOCAASLAN, Pinar EREL, Yesim AGYOL, Ali Kaan GUREN, Abdussamet CELEBI, Rukiye ARIKAN, Selver ISIK, Ozlem ERCELEP, Murat SARI, Ibrahim Vedat BAYOGLU, Osman KOSTEK Prognostic Factors Associated with Resected Osteosarcoma: Efficacy of Adjuvant Setting, Real-World Experience.UHOD , 2024 , 34 , 020-027

 

Ulusal hakemli dergilerde yayınlanan makaleler

1. Özlem Ercelep, Perran Fulden Yumuk Evaluation of Recent Targeted Treatments Güncel Göğüs Hastalıkları Serisi 2018; 6 (3): 74-84 ISSN 2147-5776

2. Özlem Ercelep, Faysal Dane Glioblastomda İlk Seri Sistemik Tedavi Türkiye Klinikleri Dergisi Tıbbi Onkoloji Erişkin Santral Sinir Sistemi Tümörleri özel sayısı 2019. p.58-60.

3.Özlem Ercelep The Current Strategies for Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer: The Place of Immunotherapy in Future Bull Urooncol 2020; 19: 104-106 DOI: 10.4274/uob.galenos.2020.1447

4.Selver Işık, Özlem Ercelep Türkiye Klinikleri Dergisi Tıbbi Onkoloji Hedefe Yönelik Ajanların İlaç Etkileşimleri ve Yan Etkileri Küçük Molekül Tirozin Kinaz İnhibitörleri EGFR  Hedefli Tedaviler (erlotinib, afatinib, gefitinib, osimertinib, dakomitinib, lapatinib) 2021.p.5-8

 

 

BİLDİRİLER:

 

Ozlem Ercelep, Neoadjuvan Kemoradyoterapi Alan Lokal İleri Rektum Kanserli Hastalarda Patolojik Tam Yanıtı Predikte Eden Faktörler 3. Uluslararsı hipokrat tıp ve sağlık bilimleri kongresi 6-7 mart 2020, Ankara

2. Nazim Can Demircan , Ozkan Alan , Tugba Basoglu Tuylu , Tugba Akin Telli , Rukiye Arikan , Furkan Cuma Cicek , Ozlem Ercelep , Mehmet Akif Ozturk , Ilknur Alsan Cetin, Rabia Ergele , Ilker Tinay, Nalan Akgul Babacan , Serap Kaya , Faysal Dane , Perran Fulden Yumuk Impact of the Charlson Comorbidity Index on Dose-Limiting Toxicity and Survival in Locally Advanced and Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib or Pazopanib 9. Avrasya Üroonkoloji Kongresi 16-20 kasım 2019

3. Abdussamet Çelebi , Alper Yaşar , Nadiye Sever , Nargiz Majidova , Rukiye Arıkan , Selver Işık , Murat Sarı , Özlem Ercelep , İbrahim Vedat Bayoğlu , Osman Köstek The relationship between c-erbB2 positivity and disease-free survival in operated non-metastatic gastric cancerThe relationship between c-erbB2 positivity and disease-free survival in operated non-metastatic gastric cancer International Asssociation of surgeons  Gastraenterologists and Oncologists IASGO 2022

4. Hilal Sağıroğlu Üstün , Abdussamet Çelebi , Ibrahim Vedat Bayoğlu, Rukiye Arıkan , Alper Yaşar , Nargiz Majidova , Nadiye Sever , Murat Sarı , Selver Işık , Özlem Ercelep , Osman Köstek What is the ideal sequence for regorafenib in the treatment of metastatic colorectal cancer? 12th International Gastrointestinal Cancers Conference 2022

5. Javid Hüseynov, Alper Yaşa , Abdussamet Çelebi , Nargiz Majidova , Nadiye Sever , Rukiye Arıkan , Selver Işık , Tuğba Akın Telli , Murat Sarı , Özlem Ercelep , İbrahim Vedat Bayoğlu, Osman Köstek Evaluation of Factors Influencıng on Progressıon-Free Survival and Overall Survival of Patients Requesting First Series Tyrosin Kinase Inhibitor for Metastatic Renal Cell Carcinoma 12.Avrasya Üroonkoloji kongresi 2022

 

KİTAP YAZARLIĞI:

 

Özlem Ercelep Kemik koruyucu tedaviler, Onkolojide Palyatif Bakım ve Yaşam Sonu Desteği ISBN 978-605-258-954-0 bölüm 19/ sayfa 127-131